{"disease":{"id":"hormone-deficiency","name":"hormone deficiency"},"drugs":{"marketed":[{"drug_id":"genotropin","indication_name":"Severe growth hormone deficiency in adulthood","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Omnitrope","generic_name":"Somatropin","company_name":"Serono","drug_phase":"marketed","molecular_target":"Dimeric GH receptors on cell membranes of target tissues","drug_class":"Recombinant human growth hormone","quality_score":10,"revenue":"446","mechanism":"Somatropin binds dimeric GH receptors on target cells, inducing intracellular signaling and GH-dependent protein synthesis including IGF-1."},{"drug_id":"somatropin-adult-cohort","indication_name":"Treatment of growth hormone deficiency in adults.","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"somatropin - adult cohort","generic_name":"somatropin-adult-cohort","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Growth Hormone Receptor","drug_class":"Growth Hormone","quality_score":10,"revenue":"446","mechanism":""},{"drug_id":"somatropin-adult-cohort","indication_name":"Treatment of adult-onset growth hormone deficiency.","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"somatropin - adult cohort","generic_name":"somatropin-adult-cohort","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Growth Hormone Receptor","drug_class":"Growth Hormone","quality_score":10,"revenue":"446","mechanism":""},{"drug_id":"somatropin-adult-cohort","indication_name":"Treatment of growth hormone deficiency in adults with a history of radiation therapy to the head.","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"somatropin - adult cohort","generic_name":"somatropin-adult-cohort","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Growth Hormone Receptor","drug_class":"Growth Hormone","quality_score":10,"revenue":"446","mechanism":""},{"drug_id":"somatropin-adult-cohort","indication_name":"Treatment of growth hormone deficiency in adults with a history of pituitary surgery.","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"somatropin - adult cohort","generic_name":"somatropin-adult-cohort","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Growth Hormone Receptor","drug_class":"Growth Hormone","quality_score":10,"revenue":"446","mechanism":""},{"drug_id":"ngenla","indication_name":"Growth hormone deficiency","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Ngenla","generic_name":"Somatrogon-Ghla","company_name":"Pfizer Ireland Pharmaceuticals","drug_phase":"marketed","molecular_target":"Growth hormone receptor","drug_class":"","quality_score":70,"revenue":null,"mechanism":"Ngenla works by binding to the growth hormone receptor, mimicking the action of natural growth hormone to stimulate growth and development."},{"drug_id":"ngenla-somatrogon","indication_name":"Short stature associated with idiopathic growth hormone deficiency in pediatric patients 2 years of age and older","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"NGENLA (Somatrogon)","generic_name":"ngenla-somatrogon","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Growth hormone receptor","drug_class":"Recombinant human growth hormone","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"ngenla-somatrogon","indication_name":"Short stature associated with other causes of growth hormone deficiency in pediatric patients 2 years of age and older","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"NGENLA (Somatrogon)","generic_name":"ngenla-somatrogon","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Growth hormone receptor","drug_class":"Recombinant human growth hormone","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"somapacitan","indication_name":"Adult growth hormone deficiency","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Sogroya","generic_name":"SOMAPACITAN","company_name":"Novo Nordisk","drug_phase":"marketed","molecular_target":"Growth hormone receptor","drug_class":"","quality_score":70,"revenue":null,"mechanism":"Sogroya works by binding to the growth hormone receptor, mimicking the action of growth hormone and stimulating growth and development."},{"drug_id":"somatropine","indication_name":"Severe growth hormone deficiency in adulthood","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"somatropine","company_name":"Sanofi","drug_phase":"phase_3","molecular_target":"Growth hormone receptor","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"lonapegsomatropin-tcgd","indication_name":"Adult Growth Hormone Deficiency","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"SKYTROFA","generic_name":"LONAPEGSOMATROPIN-TCGD","company_name":"ASCENDIS PHARMA ENCOCRINOLOGY DIV A/S","drug_phase":"marketed","molecular_target":"growth hormone (GH) receptor","drug_class":"Recombinant Human Growth Hormone [EPC]","quality_score":10,"revenue":null,"mechanism":"SKYTROFA binds to the GH receptor, triggering signal transduction and various pharmacodynamic effects, including growth stimulation in pediatric GHD."},{"drug_id":"somapacitan","indication_name":"Growth hormone deficiency in adults","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Sogroya","generic_name":"SOMAPACITAN","company_name":"Novo Nordisk","drug_phase":"marketed","molecular_target":"Growth hormone receptor","drug_class":"","quality_score":70,"revenue":null,"mechanism":"Sogroya works by binding to the growth hormone receptor, mimicking the action of growth hormone and stimulating growth and development."},{"drug_id":"somatrogon","indication_name":"Growth hormone deficiency","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Ngenla","generic_name":"somatrogon","company_name":"Pfizer Ireland Pharmaceuticals","drug_phase":"marketed","molecular_target":"Growth hormone receptor","drug_class":"","quality_score":60,"revenue":null,"mechanism":"Ngenla works by binding to the growth hormone receptor, mimicking the action of natural growth hormone."},{"drug_id":"omnitrope","indication_name":"Severe growth hormone deficiency in adulthood","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Omnitrope","company_name":"Sandoz","drug_phase":"marketed","molecular_target":"Growth hormone receptor","drug_class":"","quality_score":16,"revenue":null,"mechanism":null},{"drug_id":"somapacitan-beco","indication_name":"Adult growth hormone deficiency","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"SOGROYA","generic_name":"SOMAPACITAN-BECO","company_name":"NOVO NORDISK INC","drug_phase":"marketed","molecular_target":"Growth hormone receptor","drug_class":"","quality_score":25,"revenue":null,"mechanism":""}],"pipeline":[{"drug_id":"growth-hormone-replacement-therapy","indication_name":"Growth Hormone Deficiency","indication_type":"pipeline","phase":"discontinued","line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Growth Hormone Replacement Therapy","generic_name":"growth-hormone-replacement-therapy","company_name":"Pfizer Inc.","drug_phase":"discontinued","molecular_target":"","drug_class":"An observational study of patients who are commencing GH replacement as part of their routine NHS cl","quality_score":null,"revenue":null,"mechanism":"An observational study of patients who are commencing GH replacement as part of their routine NHS cl"}],"offLabel":[],"totalMarketed":15,"totalPipeline":1},"trials":{"data":[{"nct_id":"NCT03655223","title":"Early Check: Expanded Screening in Newborns","phase":"","overall_status":"ENROLLING_BY_INVITATION","enrollment_count":30000,"lead_sponsor_name":"RTI International","has_results":false},{"nct_id":"NCT00960128","title":"Observational Prospective Study on Patients Treated With Norditropin®","phase":"","overall_status":"COMPLETED","enrollment_count":21249,"lead_sponsor_name":"Novo Nordisk A/S","has_results":false},{"nct_id":"NCT03047369","title":"The Myelin Disorders Biorepository Project","phase":"","overall_status":"RECRUITING","enrollment_count":12000,"lead_sponsor_name":"Children's Hospital of Philadelphia","has_results":false},{"nct_id":"NCT05687474","title":"Baby Detect : Genomic Newborn Screening","phase":"","overall_status":"COMPLETED","enrollment_count":6824,"lead_sponsor_name":"Centre Hospitalier Universitaire de Liege","has_results":false},{"nct_id":"NCT03972345","title":"Influence of Adherence to Growth Hormone Therapy (GHT) With Norditropin® on Near Final Height in Patients With Growth Hormone Deficiency (GHD) and Born Small for Gestational Age (SGA)","phase":"","overall_status":"ENROLLING_BY_INVITATION","enrollment_count":750,"lead_sponsor_name":"Novo Nordisk A/S","has_results":false},{"nct_id":"NCT05110391","title":"Sperm Retrieval Rates in Non-obstructive Azoospermic Men Subjected to Gonadotropin Therapy","phase":"","overall_status":"COMPLETED","enrollment_count":616,"lead_sponsor_name":"ANDROFERT - Clinica de Andrologia e Reproducao Humana","has_results":false},{"nct_id":"NCT05509894","title":"Korean Post-marketing Surveillance Ngenla® Pre-filled Pen Injection for the Treatment of Pediatric Patients With Growth Disturbance Due to Insufficient Secretion of Growth Hormone","phase":"","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":565,"lead_sponsor_name":"Pfizer","has_results":false},{"nct_id":"NCT06542809","title":"Evaluation of the Propensity of Patients Under rhGH to Envision a Modification of Their Treatment Regimen Toward LAGH","phase":"NA","overall_status":"RECRUITING","enrollment_count":500,"lead_sponsor_name":"Cliniques universitaires Saint-Luc- Université Catholique de Louvain","has_results":false},{"nct_id":"NCT07342686","title":"Hypothalamic-Stratified Nursing Pathway for Pediatric Craniopharyngioma","phase":"","overall_status":"COMPLETED","enrollment_count":500,"lead_sponsor_name":"West China Hospital","has_results":false},{"nct_id":"NCT06709040","title":"A Study to Follow Paediatric Participants With Growth Hormone Deficiency Treated With Somapacitan for Long Term Safety Information and Clinical Parameters","phase":"","overall_status":"ENROLLING_BY_INVITATION","enrollment_count":500,"lead_sponsor_name":"Novo Nordisk A/S","has_results":false},{"nct_id":"NCT04513171","title":"Safety and Efficacy of Y-shape Pegylated Somatropin in Growth Hormone Deficiency Children","phase":"PHASE2, PHASE3","overall_status":"COMPLETED","enrollment_count":434,"lead_sponsor_name":"Xiamen Amoytop Biotech Co., Ltd.","has_results":false},{"nct_id":"NCT06455956","title":"Use of miRNAs in Growth Hormone Deficiency (GHD)","phase":"","overall_status":"RECRUITING","enrollment_count":400,"lead_sponsor_name":"University of Parma","has_results":false},{"nct_id":"NCT05718570","title":"A Study to Follow Patients With Adult Growth Hormone Deficiency (AGHD) Treated With Sogroya® for Long Term Safety Information","phase":"","overall_status":"ENROLLING_BY_INVITATION","enrollment_count":400,"lead_sponsor_name":"Novo Nordisk A/S","has_results":false},{"nct_id":"NCT02068521","title":"Versartis Long-Term Safety Study of Somavaratan","phase":"PHASE2, PHASE3","overall_status":"TERMINATED","enrollment_count":385,"lead_sponsor_name":"Versartis Inc.","has_results":false},{"nct_id":"NCT01947894","title":"A Prospective Non-Interventional Study Protocol With Primary Data Collection - Assessment Of The Long Term Treatment Outcomes Of Genotropin Treatment In Growth Hormone Deficiency (GHD) Patients","phase":"","overall_status":"COMPLETED","enrollment_count":377,"lead_sponsor_name":"Pfizer","has_results":true},{"nct_id":"NCT06263192","title":"Pregnancy Prediction Using Anti-Müllerian Hormone in Intrauterine Insemination Cycles","phase":"","overall_status":"COMPLETED","enrollment_count":342,"lead_sponsor_name":"Jose Antonio Moreno","has_results":false},{"nct_id":"NCT01580605","title":"French National Registry of Adults With Growth Hormone Deficiency Treated With Somatropin","phase":"","overall_status":"COMPLETED","enrollment_count":331,"lead_sponsor_name":"Novo Nordisk A/S","has_results":false},{"nct_id":"NCT03672617","title":"Validation of a Questionnaire That Identifies the Reasons for Non-adherence to Existing Growth Hormone Therapy","phase":"","overall_status":"COMPLETED","enrollment_count":321,"lead_sponsor_name":"Novo Nordisk A/S","has_results":false},{"nct_id":"NCT00256126","title":"Predictive Markers in Growth Hormone Deficiency (GHD) and Turner Syndrome (TS) Children Treated With SAIZEN®","phase":"PHASE4","overall_status":"COMPLETED","enrollment_count":318,"lead_sponsor_name":"Merck KGaA, Darmstadt, Germany","has_results":true},{"nct_id":"NCT02229851","title":"Trial to Compare the Efficacy and Safety of NNC0195-0092 (Somapacitan) With Placebo and Norditropin® FlexPro® (Somatropin) in Adults With Growth Hormone Deficiency.","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":301,"lead_sponsor_name":"Novo Nordisk A/S","has_results":true},{"nct_id":"NCT07173036","title":"Evaluation of (Cardio)Metabolic and Auxological Outcomes of GHD Patients Under rhGH or LAGH With Stratification According to IGF-1 Levels","phase":"NA","overall_status":"NOT_YET_RECRUITING","enrollment_count":300,"lead_sponsor_name":"Cliniques universitaires Saint-Luc- Université Catholique de Louvain","has_results":false},{"nct_id":"NCT04795570","title":"Urethral Stricture After Transurethral Resection of the Prostate/Bladder: a Prospective Study of Risk Factors","phase":"","overall_status":"UNKNOWN","enrollment_count":300,"lead_sponsor_name":"University Hospital Virgen de las Nieves","has_results":false},{"nct_id":"NCT03344458","title":"A Long-Term Trial Investigating Safety and Efficacy of TransCon hGH in Children With Growth Hormone Deficiency Who Have Completed a Prior TransCon hGH Clinical Trial","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":298,"lead_sponsor_name":"Ascendis Pharma A/S","has_results":true},{"nct_id":"NCT07126288","title":"Evaluating the Efficacy and Safety of GB08 Injection in Pediatric Patients With Growth Hormone Deficiency","phase":"PHASE2, PHASE3","overall_status":"NOT_YET_RECRUITING","enrollment_count":268,"lead_sponsor_name":"Shenzhen Kexing Pharmaceutical Co., Ltd.","has_results":false},{"nct_id":"NCT04615273","title":"A Trial to Compare the Efficacy and Safety of Once-weekly Lonapegsomatropin With Placebo and a Daily Somatropin Product in Adults With Growth Hormone Deficiency","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":264,"lead_sponsor_name":"Ascendis Pharma Endocrinology Division A/S","has_results":true},{"nct_id":"NCT02580032","title":"Validation of Two Measures for Growth Hormone Deficiency in Children, the Treatment Related Impact Measure of Childhood Growth Hormone Deficiency (TRIM-CGHD) and the Treatment Burden Measure of Childhood Growth Hormone Deficiency (TB-CGHD)","phase":"","overall_status":"COMPLETED","enrollment_count":252,"lead_sponsor_name":"Novo Nordisk A/S","has_results":false},{"nct_id":"NCT02699190","title":"LeukoSEQ: Whole Genome Sequencing as a First-Line Diagnostic Tool for Leukodystrophies","phase":"","overall_status":"COMPLETED","enrollment_count":236,"lead_sponsor_name":"Children's Hospital of Philadelphia","has_results":true},{"nct_id":"NCT05171855","title":"A Trial to Investigate Long Term Efficacy and Safety of Lonapegsomatropin in Adults With Growth Hormone Deficiency","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":220,"lead_sponsor_name":"Ascendis Pharma Endocrinology Division A/S","has_results":true},{"nct_id":"NCT06109935","title":"Special Use-results Surveillance on Long Term Use of Sogroya® in Children With Short Stature Due to Growth Hormone Deficiency Where Epiphysial Discs Are Not Closed","phase":"","overall_status":"ENROLLING_BY_INVITATION","enrollment_count":200,"lead_sponsor_name":"Novo Nordisk A/S","has_results":false},{"nct_id":"NCT06694506","title":"BELux Children OutcoME During A(@)Dulthood With GHD","phase":"NA","overall_status":"NOT_YET_RECRUITING","enrollment_count":200,"lead_sponsor_name":"Cliniques universitaires Saint-Luc- Université Catholique de Louvain","has_results":false},{"nct_id":"NCT05230550","title":"Post-Marketing Surveillance (Special Use-results Surveillance on Long-term Use) With Sogroya®","phase":"","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":200,"lead_sponsor_name":"Novo Nordisk A/S","has_results":false},{"nct_id":"NCT03811535","title":"A Research Study in Children With a Low Level of Hormone to Grow. Treatment is Somapacitan Once a Week Compared to Norditropin® Once a Day (REAL4)","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":200,"lead_sponsor_name":"Novo Nordisk A/S","has_results":true},{"nct_id":"NCT00567385","title":"Liquid Somatropin Formulation in Children With Growth Hormone Deficiency","phase":"PHASE4","overall_status":"COMPLETED","enrollment_count":176,"lead_sponsor_name":"Novo Nordisk A/S","has_results":false},{"nct_id":"NCT04867317","title":"Growth Hormone Replacement Therapy in Veterans With Mild Traumatic Brain Injury (mTBI) and Adult Growth Hormone Deficiency (AGHD)","phase":"PHASE3","overall_status":"RECRUITING","enrollment_count":172,"lead_sponsor_name":"VA Office of Research and Development","has_results":false},{"nct_id":"NCT05603936","title":"Adaption and Testing of the Quality of Life in Short Stature Youth (QoLISSY) Questionnaire for Parents With Children From 0-4","phase":"","overall_status":"UNKNOWN","enrollment_count":168,"lead_sponsor_name":"Universitätsklinikum Hamburg-Eppendorf","has_results":false},{"nct_id":"NCT01563926","title":"Evaluating Acceptance of New Liquid Somatropin Formulation in Children With Growth Hormone Deficiency","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":168,"lead_sponsor_name":"Novo Nordisk A/S","has_results":false},{"nct_id":"NCT04633057","title":"A Study to Evaluating the Efficacy and Safety of Recombinant Long-acting Human Growth Hormone (TJ101) in Children With Growth Hormone Deficiency","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":168,"lead_sponsor_name":"TJ Biopharma Co., Ltd.","has_results":false},{"nct_id":"NCT02781727","title":"A Phase 3 Trial of the Safety, Tolerability and Efficacy of TransCon hGH Weekly Versus Daily hGH in Children With Growth Hormone Deficiency (GHD)","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":162,"lead_sponsor_name":"Ascendis Pharma Endocrinology Division A/S","has_results":true},{"nct_id":"NCT04252001","title":"Growing up With the Young Endocrine Support System (YESS!)","phase":"NA","overall_status":"NOT_YET_RECRUITING","enrollment_count":160,"lead_sponsor_name":"dr. Laura C. G. de Graaff-Herder","has_results":false},{"nct_id":"NCT02558829","title":"Validation of Macimorelin as a Test for Adult Growth Hormone Deficiency","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":157,"lead_sponsor_name":"AEterna Zentaris","has_results":true},{"nct_id":"NCT05645211","title":"The AgRP and GH/IGF-1 Axis in Children","phase":"","overall_status":"NOT_YET_RECRUITING","enrollment_count":156,"lead_sponsor_name":"Columbia University","has_results":false},{"nct_id":"NCT04762615","title":"Impact of Underlying Renal Disease and Immunosuppressive Regimen on Ovarian Reserve in Renal Patients","phase":"","overall_status":"COMPLETED","enrollment_count":153,"lead_sponsor_name":"Wroclaw Medical University","has_results":false},{"nct_id":"NCT03305016","title":"A Safety, Tolerability and Efficacy Study of TransCon hGH in Children With Growth Hormone Deficiency","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":146,"lead_sponsor_name":"Ascendis Pharma Endocrinology Division A/S","has_results":true},{"nct_id":"NCT07450001","title":"A Study of GenSci134 in Children With Growth Hormone Deficiency (PGHD)","phase":"PHASE1, PHASE2","overall_status":"NOT_YET_RECRUITING","enrollment_count":128,"lead_sponsor_name":"Changchun GeneScience Pharmaceutical Co., Ltd.","has_results":false},{"nct_id":"NCT04335227","title":"Yoga Therapy and Aerobic Exercise on Anti-Mullerian Hormone in Young Women With Polycystic Ovary Syndrome","phase":"NA","overall_status":"UNKNOWN","enrollment_count":128,"lead_sponsor_name":"Maharishi Markendeswar University (Deemed to be University)","has_results":false},{"nct_id":"NCT00519558","title":"Growth Hormone Deficiency in Adults (GHDA)","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":121,"lead_sponsor_name":"Novo Nordisk A/S","has_results":false},{"nct_id":"NCT07259564","title":"A Study of GS3-007a for Oral Suspension in the Diagnosis of Adult Growth Hormone Deficiency (AGHD)","phase":"PHASE2","overall_status":"NOT_YET_RECRUITING","enrollment_count":120,"lead_sponsor_name":"Changchun GeneScience Pharmaceutical Co., Ltd.","has_results":false},{"nct_id":"NCT03015909","title":"Evaluation of the Ease of Use, Preference, and Safety of EutropinPen Inj.","phase":"PHASE4","overall_status":"COMPLETED","enrollment_count":116,"lead_sponsor_name":"LG Life Sciences","has_results":false},{"nct_id":"NCT00184743","title":"Long-term Trial on Growth Hormone Deficiency in Adults (GHDA)","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":112,"lead_sponsor_name":"Novo Nordisk A/S","has_results":false},{"nct_id":"NCT04970654","title":"A Research Study in Chinese Children With a Low Level of Hormone to Grow. Treatment is Somapacitan Once a Week Compared to Norditropin® Once a Day.","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":110,"lead_sponsor_name":"Novo Nordisk A/S","has_results":true}],"total":50},"guidelines":[],"source":"Drug Landscape verified database"}